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Abstract 
β-methylphenylethylamine (BMPEA) was first synthesized in the 1930’s as a potential stimulant 
and amphetamine replacement. It was expected to act as an indirect sympathomimetic agent that 
binds to peripheral α- and β- adrenergic receptors to control vascular responses in peripheral 
sites. The effects of BMPEA were never studied in humans, but due to its structural similarity to 
amphetamines as well as the effects noticed in animal studies in the 1920’s and 1930’s, BMPEA 
was assumed to work as a vasoconstrictor. In the current study, porcine mesenteric arteries were 
used as a model following confirmation of arterial viability with the known constrictor, KCl, and 
the known dilator, nitroprusside. Using an isolated vascular ring protocol, arteries were exposed 
to increasing concentrations (1x10-7M to 1x10-3M) of BMPEA to determine changes in vascular 
reactivity. The results were compared to constriction in response to the known α-adrenergic 
agonist phenylephrine (1x10-7M to 1x10-4M), and to dilation in response to the known β-
adrenergic agonist isoproterenol (1x10-7M to 1x10-4M). No significant change in arterial tension 
was noted when BMPEA was added as a potential constrictor, or when it was added as a 
potential dilator after pre-constriction with KCl. Phenylephrine induced a significant increase in 
tension, serving as a positive control for α-adrenergic-mediated vasoconstriction. However, 
isoproterenol did not show a decrease in tension with administration of increasing concentrations 
as expected. The presence of an α-adrenergic receptor-mediated response in the tested porcine 
vasculature was confirmed by incubation with 1x10-5M of the α-adrenergic antagonist 
phentolamine. This was effective in blocking the phenylephrine-induced constriction. BMPEA 
caused no change in tension when administered following phentolamine incubation.  Propranolol 
(1x10-5M) was used to block β-adrenergic receptors with the addition of BMPEA and 
isoproterenol. BMPEA showed no change in arterial tension for any of these experiments, and it 
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was concluded that it does not act as a vasoactive agent to constrict or dilate arteries in porcine 
mesenteric vasculature. Further studies are needed to determine whether BMPEA elicits a 
vascular response in other organ systems, or if it indeed demonstrates no vascular effect in this 
species. 
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Introduction 
Amphetamines and Sympathetic Action. Amphetamines are a group of compounds that 
act on a and b adrenergic receptors and that are similar in action to dopaminergic, 
catecholaminergic, and serotonergic agonists.  As such, they are stimulators of both the central 
and peripheral nervous systems and can elicit vascular effects. As catecholaminergic agonists, 
they can induce tachycardia and vasoconstriction with a concomitant increase in blood pressure. 
Amphetamines also mimic serotonergic actions that result in vasoconstriction (Handley, 2016).  
One pathway through which amphetamines work to elicit these responses is by targeting 
vascular smooth muscles in peripheral sites. Smooth muscles are found in blood vessel walls, the 
digestive tract and associated organs such as the gall bladder. Smooth muscles are also found in 
tissues of the urinary tract such as the bladder and ureter linings, in airways, in reproductive 
organs and in the ocular muscles of the eye. They contract in response to electrical signals, 
chemical signals, or both, and are regulated by the autonomic nervous system. The receptors for 
these signals in smooth muscles are not localized to specific regions, as is the case for skeletal 
muscle. Instead, they are located along the entire length of the smooth muscle. Most smooth 
muscles do not receive parasympathetic signals and only induce sympathetic effects, including 
vascular smooth muscle contraction. These contractions are achieved via an influx of calcium 
from the extracellular fluid or from the sarcoplasmic reticulum, resulting in a phosphorylation 
cascade that ends in phosphorylation of myosin light chains and activation of myosin ATPase.  
Sympathetic nerves also innervate cardiac muscle to increase heart rate, contractility, 
conduction velocity, and rate of relaxation. In blood vessels, the sympathetic nerves elicit 
vasoconstriction of arteries and arterioles, resulting in increased friction between the vessel and 
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the blood, and increased resistance to the blood flow through the constricted artery, as well as a 
decrease in distal blood flow. Ohm’s law states that the current through two points of a 
conductor is directly proportional to the voltage across the two points, and is inversely 
proportional to the resistance through the system. An analogue of this law is used to describe 
blood flow, and shows that blood flow is equal to the difference in pressure between two points 
in the vasculature (also known as driving pressure, pressure gradient and perfusion pressure) 
divided by the resistance given by the blood vessel. Thus the increased resistance due to 
constriction results in increased arterial pressure.  
 
Changes in blood pressure can have many health ramifications. Persistent high blood 
pressure, or hypertension, can cause weakened areas in vessel walls that can result in ruptures 
and bleeding into surrounding tissues. This is particularly problematic when it occurs in arteries 
in the brain, as it can result in hemorrhagic stroke and loss of neurological function. Should the 
rupture occur in large arteries in the abdomen, the large amount of blood lost can result in a rapid 
loss in pressure. This can make it difficult for the blood flow to overcome gravity, resulting in 
decreased oxygen to the brain. Large aneurysms such as these can be fatal. 
The prolonged use of amphetamines and the resulting vasoconstriction, increased heart 
rate, and increased blood pressure can have major health ramifications, and long term use of 
amphetamines are associated with dilated cardiomyopathy, and myocardial infarction. In 
addition, the abuse of amphetamines and their analogs can result in seizures, hypertension, 
psychosis, tachycardia, stroke, myocardial infarction, or death. Unfortunately, such abuse and 
prolonged use is common in the United States, Europe and Australasia. (Handley et al., 2016). 
Trace amounts of amines and other analogs of amphetamine can also be found in the body 
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naturally due to ingestion of herbs (Broadley et al., 2010). These analogs include tyramine, β-
phenylethylamine (β-PEA), octopamine, tryptamine and other compounds based on 
phenylethylamine. Many of these cause vasoconstriction and elevated blood pressure (Broadley 
et al., 2010).  
Adrenergic Receptors. Sympathetic agents such as catecholamines, and amphetamines 
act on adrenergic receptors to achieve a myriad of sympathetic actions. There are subclasses of 
adrenergic receptors, and the action elicited by activation of these adrenergic receptors is 
dependent on the subtype acted upon. This can result in different sympathetic actions at different 
locations due to the ratio of the adrenergic receptor subtypes present.  
 α-adrenergic receptors induce vasoconstriction of veins and decreased motility of 
intestinal smooth muscle. These receptors can be further subcategorized into α1 and 2 receptors, 
and further yet into α1A,B and D, and into α2A,B and C receptors.  Activation of α1 receptors results 
in smooth muscle contraction, including vasoconstriction in the skin, intestines, kidney and 
brain, and smooth muscles associated with the genitourinary systems. Actions of α2 receptor 
activation include inhibition of insulin and glucagon release in the pancreas, and contraction of 
gastrointestinal sphincters. 
β adrenergic receptors  include β1, β2, and β3 subcategories. Specific actions of β1 
receptors included increase in heart rate, conductivity and stroke volume resulting in increased 
cardiac output. Activation of β2 receptors results in smooth muscle relaxation. This includes 
relaxation of bronchial and gastrointestinal smooth muscles, as well as vasodilation of blood 
vessels. Activation of β3 adrenergic receptors results in the increased lipolysis of adipose tissue. 
Amphetamine Analog BMPEA.  Amphetamines and their analogs act on both α and β 
adrenergic receptors throughout the body, and it is the increased expression of specific subtypes 
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over the others that determines which effects are elicited. One analog of amphetamine is β-
methylphenylethylamine (BMPEA), a substance that was first synthesized in the 1930’s as a 
potential stimulant and amphetamine replacement (Hartung et al., 1931). It was expected to act 
as an indirect sympathomimetic agent that would act on peripheral α- and β- adrenergic receptors 
to control the vascular response in peripheral sites. Due to its structural similarity to 
amphetamines, it was expected to have many of the same vascular effects. However, the 
physiological effects and efficacy of BMPEA have never been systematically studied and remain 
unconfirmed (Cohen et al., 2016). Structural similarities between BMPEA, amphetamine, and 
other common amphetamine analogs are shown in Figure 1. 
	  
Figure 1. Structure of Amphetamine, BMPEA, and Epinephrine (Cohen et al., 2016; 
Neal et al, 2016) 
 
BMPEA in Animal Studies. While the effect of BMPEA in humans is unknown, a few 
animal studies have been performed. In the 1930s and 1940s, BMPEA was studied in dogs and 
cats where it was shown to increase blood pressure and heart rate in these animals (Graham et 
al., 1944; Tainter et al., 1943; Warren et al., 1943).  It was also shown to cross the blood-brain 
barrier in rats (Mosnaim et al., 2013). Further study is needed to determine whether BMPEA has 
similar effects in humans.  Another study of BMPEA analogs  α -MPEA and BPEA in Swiss 
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albino mice showed elevated locomotor activity, hyperexcitability and increased fighting 
behavior upon administration of these compounds (Mosnaim et al., 2015). 
BMPEA and Stroke. One anecdotal study of BMPEA in humans does exist. A study by 
Cohen et al. (2015) indicated that exercise in combination with BMPEA may have caused 
hemorrhagic stroke in a 53-year-old woman. The patient in this case study had no previous 
history of stroke, but had taken 13g of a sports supplement for the first time immediately prior to 
the onset of her stroke. She was taking no other medications. The supplement that the patient 
took was not labeled with BMPEA or Acacia rigidula, a proposed natural source of BMPEA, but 
upon testing the supplement, it was determined to have 290mg of BMPEA per dose (Cohen et 
al., 2015). Given the increased risk of stroke with amphetamine overdose (Handley et al., 2016), 
and considering the structural similarity of BMPEA and amphetamines, the proposed link 
between this woman’s stroke and BMPEA is not unexpected. However, this case was anecdotal, 
and further study would be needed to confirm a causative effect. Thus the effect of BMPEA in 
humans is still unknown.  
BMPEA as a Supplement. The presence of BMPEA in dietary supplements such as that 
taken by the woman in the aforementioned study is not uncommon. Due to the fact that the 
effects of BMPEA in humans were never studied, it has never been introduced as a 
pharmaceutical drug. However, in 2013 the FDA identified BMPEA in supplements that 
contained Acacia rigidula, a shrub native to Texas (Cohen et al., 2016). Cohen et al. 
demonstrated the continued presence of BMPEA in these supplements following this FDA 
finding.  Twenty-one supplements containing Acacia rigidula available for sale in the United 
States were included in the study. Three of these also listed a synonym for BMPEA. These 
supplements where marketed to consumers to enhance athletic performance, weight loss, or to 
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increase cognition. The research team found BMPEA in eleven of the supplements tested, in 
amounts from 2.9mg to 93.3mg per maximum recommended dose of supplement (Cohen et al., 
2016). Despite these findings, and despite marketing of BMPEA as an extract of Acacia rigidula, 
BMPEA has never been extracted from any natural source, including Acacia rigidula or any 
other plant. Cohen et al. suggests that the presence of BMPEA in Acacia rigidula containing 
supplements is instead indicative that BMPEA is made synthetically and added to supplements to 
produce the targeted physiologic effects of said supplements (Cohen et al., 2016).  
Due to its unknown effects, consumers should be wary of consuming supplements that 
may contain BMPEA, including supplements that list Acacia rigidula on the label. This is 
particularly important for athletes who use “natural” supplements. Dietary supplements are not 
controlled by the FDA, so many athletes are not aware that the supplements they are taking may 
contain substances that are recognized as doping substances (de Hon et al., 2007). This has often 
led to athletes failing drug tests following the implementation of new detection methods by 
testing laboratories.  Due to its similarity to amphetamine, BMPEA has been classified by the 
World Anti-Doping Agency as one of these banned stimulants (Chołbińsk et al., 2014), and 
many athletes have failed doping urine tests due to the lack of public association of BMPEA with 
Acacia rigidula labels (Cohen et al., 2016). 
BMPEA and This Study. As an amphetamine analog, consumption of BMPEA is risky. 
Anecdotal evidence suggests increased risk of hemorrhagic stroke, and preliminary animal 
studies indicate that BMPEA might have vascular effects. These potential effects, combined with 
the general lack of information on the effects of BMPEA in human subjects, makes the presence 
of BMPEA in dietary supplements concerning. BMPEA is banned by drug-screening agencies, 
and it can be present without disclosure on product labels. There is concern for athletes and the 
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common consumer alike as the adverse effects of BMPEA are not known.  In this study, we 
intend to study the vascular effects of BMPEA to determine whether it is likely to be harmful for 
human consumption.  
Specific aim number 1. Determine whether BMPEA has any effect on vascular 
reactivity in the mesenteric arteries. To determine whether BMPEA elicits a vasoconstrictive 
effect, it was administered to vascular rings for comparison to the constriction caused by a 
known α-adrenergic agonist. To determine whether it instead elicits a vasodilation response, it 
was added after pre-constriction with a known constrictor, and compared to the action of a 
known β-adrenergic dilator. Due to the vasoconstrictive effects of amphetamine and the animal 
studies that indicate that BMPEA may increase blood pressure, it was expected that BMPEA 
would engage a-adrenergic receptors to elicit a vasoconstrictive effect. 
Specific aim number 2. Confirm the α/β adrenergic response in porcine mesenteric 
vasculature via pharmacologic techniques. Amphetamines work on α and β adrenergic receptors 
to elicit either vasoconstriction or vasodilation responses respectively. BMPEA is thus expected 
to act along similar pathways. To confirm that α and β adrenergic responses in the porcine 
vessels studied are intact, α and β antagonists were used to block these receptors before 
administration of BMPEA and positive controls. Should the controls or BMPEA elicit a 
vasoactive response via these receptors, the administration of the antagonists should block said 
response. 
Drugs Used in Experimentation. In order to test the effects of BMPEA in the selected 
vasculature, it was tested against known vasoconstrictors, vasodilators, and known α and β 
agonists. In addition, α and β antagonists were used to block action and to confirm the method of 
action. Table 1 illustrates all drugs used in this study, and their respective purpose/action.  
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Table 1. Drugs Used in Study 
Drug/supplement/chemical Purpose/action 
BMPEA Supplement of study; potential α/β adrenergic agonist and 
vasoactive substance 
KCl Known vasoconstrictor. Agent used for viability testing 
Sodium Nitroprusside Known vasodilator. Agent used for viability testing 
Phenylephrine Known vasoconstrictor. Nonspecific α-adrenergic agonist and 
positive control  
Isoproterenol Known vasodilator. Nonspecific β-adrenergic agonist and 
positive control 
Phentolamine Nonspecific α-antagonist 
Propranolol Nonspecific β-antagonist 
 
Isoproterenol was used as a positive control for β-adrenergic receptor-mediated 
vasodilation. Isoproterenol is a sympathomimetic amine that has been a frequently used 
pulmonary vasodilator since the early 1960s. It acts as a β-adrenergic agonist and acts on β-
adrenergic receptors throughout the body while leaving α-adrenergic receptors unaffected. It has 
been shown to increase cardiac output via intrinsic effects, and it has been shown to cause 
peripheral vasodilation (Palevsky et al., 1985).  Phentolamine was used as a nonspecific α-
adrenergic blocker (Eason et al., 1992) as a 1x10-5M solution, a concentration that has been 
shown to be effective in blocking the action of α-adrenergic agonists after an hour-long 
incubation (Duckles et al., 1976).  Aliquots were prepared and stored in the freezer. Propranolol 
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was used as a nonspecific β-adrenergic antagonist (Nayler et al., 1967) that leaves α-adrenergic 
receptors unaffected (Propranolol Hydrochloride Injection).  
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Methods 
Model used. Pigs are one of the major non-rodent animal models for translational 
research, surgical and pharmaceutical testing (Swindle et al., 2012). We chose to use the porcine 
mesenteric vasculature as a pre-clinical model to determine whether additional studies of 
BMPEA on the human vasculature would be warranted. Although our lab is investigating the 
effects of BMPEA in multiple organ systems of the pig, the catecholaminergic response to 
amphetamines suggests that the mesenteric arteries would be a sensitive site for studying the 
effects of BMPEA as well. 
 Blood to the abdomen is supplied via the abdominal aorta. The superior mesenteric artery 
branches from the aorta to provide blood to the small intestines. Jejunal and ileal arteries branch 
off along the length of the superior mesenteric artery before branching in to anastomotic loops 
(arcades) and then from these loops to the arteriae rectae (straight arteries) to the loops of the 
jejunum and ilium. Arteries in this study were dissected from the mesenteric fascia and were 
determined to be either a segment of anastomotic loop or of the arteriae rectae. 
General Procedure. Porcine small intestines were obtained from DeVries Meats in 
Coopersville, Michigan. To reduce tissue deterioration and cell death and the amount of time 
between the sacrifice of the animals and subsequent experimentation, the organs were obtained 
directly from the production line. The intestines were placed directly in bags, and then on ice for 
travel. Segments of anastomotic loops or arteriae rectae mesenteric arteries of approximately 1-
5mm in diameter were dissected from the intestines upon arrival at the lab. These arteries were 
adhering parenchymal tissue without damaging the arteries to reduce any potential confounding 
vascular response originating from surrounding tissues. The ends of the dissected arteries were 
cut off to remove any potentially damaged tissue, resulting in arterial ring segments 
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approximately 4mm long. The dissected arterial segments were then placed in Krebs- Henseleit 
buffer solution. This is a common buffer used to mimic normal physiological conditions when 
studying the vasculature ex vivo, and has a pH of 7.4 when equilibrated with 95% O2/5% CO2 
(Bailey et al., 1978).  Approximate arterial ringlet size is illustrated in Figure 2. 
 
Figure 2. Porcine Mesenteric Arterial Ring Size 
Comparison. 
 
 
 
 
 
Isolated Vascular Ring Protocol. Vascular response of the arteries was tested using the 
isolated vascular ring protocol. This is a standard procedure used to measure the effects of 
constrictive and dilative agents on the vasculature in vitro. It can be used to produce dose-
response curves in response to potential vasoactive substances. The procedure eliminates many 
confounding variables such as circulating hormones, changes in blood flow, or modulation via 
the nervous system and allows for the potential vasoactivity of the vessels to be measured in 
precisely defined conditions. These in vitro measurements thus indicate the constrictive or 
dilative responses of the vessels to the tested substance, which in turn may provide evidence 
justifying further study in vivo (Yildiz et al., 2013). 
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The set up for the isolated vascular ring procedure is illustrated in Figure 3. The organ 
baths were filled with 25mL of Krebs-Henseleit buffer and maintained at 37ºC. Two hooks were 
carefully placed through the lumen of the arterial rings. One of these hooks allowed for manual 
adjustment of vessel tension, and the other was connected to an isometric force transducer. This 
allowed for adjustment of the artery to a controlled resting tension, and for the measurement of 
tension changes associated with contraction and dilation. 
 
 
Figure 3. Experimental Set Up.  The artery was suspended in Krebs-Henseleit buffer. Arterial 
resting tension was manipulated with the micromanipulator hook and changes in arterial tension 
were recorded with a force transducer. Organ baths were maintained at 37°C. Data was collected 
via iWorx Amplifier (Yildiz et al., 2013) 
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The Labscribe program produced by iWorx was used to visualize the force measured by 
the force transducers (Grass Instruments), which were calibrated with 40g weights prior to each 
experiment.  Arterial segments from four different pigs were used for each lab session, one 
segment for each organ bath. Each bath was filled with 25mL of Krebs buffer, and 95% O2/5% 
CO2 was bubbled into the buffer. Passive tension on the arteries was adjusted to 7g, and was 
adjusted every 10 minutes for 45-60minutes, or until the recorded tension remained unchanged 
within a ten-minute interval.  The buffer was changed three times during the calibration to avoid 
accumulation of metabolic waste.   
Artery Viability. To check the viability of the arteries, each artery was treated with 
increasing concentrations of the vasoconstrictor KCl.  A stock solution of 0.601M KCl was 
prepared by adding 2.24g of KCl to 50mL of deionized water. Increasing volumes of stock 
solution were added every 5 minutes to create total concentrations of 0.015M, 0.030M, 0.045M 
and 0.060M.  Prior to each addition of KCl, an equivalent volume of buffer was removed to 
maintain calculated concentrations. If the arteries were viable, they exhibited a stepwise increase 
in tension as illustrated in Figure 4. If vessels were unresponsive, they were washed three times 
with fresh buffer to remove residual KCl and were adjusted to 7g of passive tension. Following 
this the arteries were again treated with 0.015M, 0.030M, 0.045mM and 0.060M KCl to achieve 
the stepwise increase in tension. 
The ability of the mesenteric arteries to dilate was confirmed by treatment with sodium 
nitroprusside (SNP).  A 1x10-2 M stock solution of SNP was prepared by adding 0.149g SNP to 
50 mL of filtered water. Following pre-constriction with KCl, increasing concentrations of SNP 
were added to each organ bath. 
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Vessels that did not show an increased tension of at least 3g in response to KCl were 
excluded from this study. Arteries that showed an increased constriction with KCl, and a return 
to a lower tension with dilator SNP, were considered viable.  
 Specific Aim 1. To determine if BMPEA is a vasoconstrictor, the addition of BMPEA 
was compared to the addition of phenylephrine, an α-adrenergic receptor agonist and potent 
vasoconstrictor (Berthelsen et al., 1977).  To eliminate any confounding effects, BMPEA and 
phenylephrine organ baths were washed with 25mL of Krebs buffer three times for 5 minutes 
before testing the other compound. This would result in a return to a passive tension of 7g. The 
temperature of the buffer bath was measured at the end of the 5 minute intervals to confirm that 
the bath temperature was maintained at 37 °C. The administration of BMPEA and phenylephrine 
was randomized to minimize an ordering effect.  
The viability of the arteries was tested with KCl and SNP. Following this, the arteries 
were adjusted to 7g and contracted with KCl prior to being tested with BMPEA.  45mM of KCl 
was administered to each bath and was left to equilibrate for 45-60 minutes. At this point, the 
arteries would reach an approximately asymptotic line at a constricted tension. BMPEA was then 
administered in five minute intervals to reach final concentrations of 1x10-7M, 1x10-6M,      
1x10-5M, and 1x10-4M.  
Isoproterenol was used as a positive control for vasodilation. Arteries were pre-
constricted with 45mM KCl, and were left to equilibrate for 45-60 min. Following this, 1x10-7M, 
1x10-6M, 1x10-5M and 1x10-4M concentrations of isoproterenol were administered at 5 minute 
intervals. 
Specific Aim 2. For each procedure in specific aim 2, an n of 6-8 viable arteries was 
obtained. Following viability confirmation, phentolamine was added to each organ bath to create 
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a final concentration of 1x10-5M. The vessels incubated for an hour before administration of 
BMPEA and phenylephrine. The arteries were not washed prior to administration of BMPEA 
and phenylephrine. BMPEA and phenylephrine were administered to separate arteries in five 
minute intervals to achieve final concentrations of  1x10-7-1x10-4 M and 1x10-7-1x10-3 M for 
BMPEA and phenylephrine respectively. 
  A final propranolol concentration of 1x10-5M was used and was incubated for an hour 
while the arteries were pre-constricted with 45mM KCl. Following pre-constriction and 
propranolol incubation, BMPEA and isoproterenol were administered to separate arteries in 5 
minute intervals to achieve final concentrations of 1x10-7-1x10-4 M and 1x10-7-1x10-3 M 
respectively. 
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Analysis 
All viable arterial tensions were charted in an Excel file. This can be seen in Appendix 1. 
Average tensions were calculated for every dose of the drugs tested. Standard error of the mean 
was calculated for these values by dividing the standard deviation by the square root of n. The 
standard error was calculated instead of standard deviation because it gives the standard error 
after adjusting for small samples sizes. This is typical for physiology experiments. JMP 
statistical analysis software was used for statistical analysis. A one-way ANOVA was used to 
determine whether there was any significant difference in arterial tension across different doses 
of a given drug. If significant differences were observed, a Tukey-Kramer test was used for post 
hoc analysis. An α of 0.05 was used for all statistical analysis. Please see statistical outputs in 
Appendix 2. A minimum n of 8 was obtained for each set of experiments in specific aim 1and an 
n of 6-8 was obtained for each set of experiments in specific aim 2. 
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Results 
Viability of the arteries was tested with known constrictor KCl, and with known 
vasodilator SNP. Arteries that did not show an increase in tension of at least 3g with the 
administration of KCl, and then a subsequent decrease in tension with the administration of SNP 
were not included in the study. A total of 62 arteries were considered viable for this study.  
Artery tensions for administration of all substances were monitored using Labscribe outputs 
generated from a force transducer. Concentrations of the drugs administered were noted by 
inserting labels in the Labscribe program, and each row in the output indicates a different artery 
and buffer bath. Sample Labscribe outputs are exhibited in Figure 4 and 5 for validity testing 
with KCl and SNP respectively.  
 
Figure 4. Addition of 0.015M, 0.030M, 0.045M and 0.060M of KCl to Mesenteric Arteries 
in 5 Minute Increments.  
        
   
 
 
 
 
 
Figure 5. The Response of Mesenteric Arteries to Increasing Concentrations of SNP.  
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Average tensions for KCl at each concentration, as well as average tensions for SNP, 
with standard error, are shown in Tables 2a and 2b respectively. Administration of 0.060M KCl 
yielded an average increase in tension to 26.91g, indicating that KCl was successful as a 
vasoconstrictor. In turn, SNP mediated an average decrease to 18.82g at 10-4M, with an average 
change of 6.9g. Thus, all arteries included in the study proved to be viable, and capable of 
vasoconstriction and vasodilation. 
Table 2a. The Response of Mesenteric Arteries to Increasing Concentrations of KCl 
n Concentration Average tension (g) Standard Error 
62 0.015M 7.37 0.33 
62 0.030M 19.26 2.05 
62 0.045M 25.45 2.14 
62 0.060M 26.91 1.99 
 
Table 2b. The Response of Mesenteric Arteries to Increasing Concentrations of SNP 
n Concentration (M) Average tension (g) Standard Error 
62 1x10-7 25.72 2.02 
62 1x10-6 25.09 1.94 
62 1x10-5 23.59 1.83 
62 1x10-4 18.82 1.43 
 
Graphical representation of these average tensions indicates an increased average arterial 
tension with increased concentrations of KCl as illustrated in Figure 6a. A one-way ANOVA 
indicated that the mean tensions at different KCl concentrations were significantly different with 
26	
	
a significance value less than 0.0001. Tukey-Kramer post hoc analysis showed significance 
between 0.015M and 0.030M, 0.015M and 0.045M, and 0.015M and 0.060M with p value 
<0.0001 for all three sets, and significance between 0.030M and 0.060M with a p-value of 
0.0110. The difference between the mean tensions at 0.030M and 0.045M, as well as between 
mean tensions at 0.045M and 0.060M were not significant however, with p-values of 0.0775 and 
0.8883 respectively. 
Similarly, average tensions decreased with increasing concentrations of SNP as 
illustrated in Figure 6b, with the average tension decreasing by 6.89g between 10-7 M and 10-4M 
SNP. A one-way ANOVA was significant with a value of 0.0359. Tukey-Kramer indicated 
significance between SNP concentrations of 1x10-7M and 1x10-4M with a p-value of 0.0419.  
 
Figure 6a. Average Mesenteric Arterial Tension with Administration of KCl. Graphical 
representation indicates a visual increase in tension between 0.015M and 0.030M, as well as 
between 0.030M and 0.060M. One way ANOVA confirms this and showed significant changes 
in average tension between 0.015M and 0.030M, 0.015M and 0.045M,  0.015M and 0.060M  and 
between 0.030M and 0.060M with p values of  <0.0001, <0.0001, <0.0001, and  0.0110 
respectively. The mean tensions between 0.030M and 0.045M, and between 0.045M and 0.060M 
were not significant, α=0.05. 
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Figure 6b. Average Mesenteric Arterial Tension with Administration of SNP. Graphical 
representation indicates a visual decrease in tension between 1x10-7 and 1x10-4 M. One way 
ANOVA confirms this and showed significance of 0.0359, and in particular a significant 
difference in average tension between 1x10-7 M and 1x10-4 M  with a p value of 0.0412, α=0.05. 
 
The working hypothesis for this study is that BMPEA acts on α-adrenergic receptors to 
mediate vasoconstriction in the porcine mesenteric vasculature studied. Thus BMPEA was 
administered in increasing concentrations and compared to the effects of the known α-adrenergic 
agonist phenylephrine. Average arterial tensions at different BMPEA and phenylephrine 
concentrations are shown in Table 3a and 3b respectively.  The average arterial tension with the 
administration of BMPEA stayed within 1g of an average tension of 6g, indicating no obvious 
increase in tension.  However, administration of phenylephrine yielded an increase in average 
tension from 6.62g to 16.37g, indicating that it was successful as a positive control for 
vasoconstriction. 
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Table 3a. The Response of Mesenteric Arteries to Increasing Concentrations of BMPEA as a 
Potential Vasoconstrictor   
n Concentration (M) Average tension (g) Standard Error 
10 1x10-7 6.61 0.18 
10 1x10-6 6.21 0.20 
10 1x10-5 5.99 0.23 
10 1x10-4 5.86 0.24 
10 1x10-3 5.86 0.25 
 
 
Table 3b. The Response of Mesenteric Arteries to Increasing Concentrations of Phenylephrine as 
a Positive control for Vasoconstriction  
n Concentration (M) Average tension (g) Standard Error 
10 1x10-7 6.62 0.19 
10 1x10-6 9.94 1.33 
10 1x10-5 18.29 2.01 
10 1x10-4 16.37 2.18 
 
Graphical representation supports these findings, and indicates no difference in average 
arterial tension at different concentrations of BMPEA as indicated by Figure 7. This is confirmed 
with a one-way ANOVA with an F Ratio of 2.0336 and a prob>F of 0.1057. Likewise, graphical 
representation supports the findings that phenylephrine was successful as a vasoconstrictor 
(Figure 7). A one-way ANOVA confirmed a significant difference between arterial tensions with 
a significance value of less than 0.0001.  Tukey-Kramer post hoc analysis specifically indicated 
significant differences between arterial tensions at phenylephrine concentrations of 1x10-7M and 
1x10-5M, 1x10-7M and 1x10-4M, 1x10-6 M and 1x10-5M, and 1x10-6M and 1x10-4M with p values 
of <0.0001, 0.0008, 0.0046 and 0.0391 respectively. 
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Figure 7. Average Mesenteric Arterial Tension with Administration of BMPEA, 
Phenylephrine, BMPEA with Phentolamine Blockade, and Phenylephrine with 
Phentolamine Blockade. BMPEA: Graphical representation indicates no visual difference 
between mean artery tensions at different concentrations of BMPEA. This is confirmed with a 
one-way ANOVA with a p-value 0.1057, α=0.05. Phenylephrine: Graphical representation 
indicates a visual increase in mean artery tension with the administration of phenylephrine. One 
way ANOVA indicated significant difference in mean artery tensions with a significance of less 
than 0.0001. Tukey-Kramer post hoc analysis specifically indicated significant difference 
between artery tensions at phenylephrine concentrations of 1x10-7M and 1x10-5M,  1x10-7M and 
1x10-4M, 1x10-6 M and 1x10-5M  and 1x10-6M and 1x10-4M with p values of <0.0001, 0.0008, 
0.0046 and 0.0391 respectively. There was no significant difference between mean tensions at 
1x10-5 M and 1x10-4M with p-value of 0.8373, α=0.05. BMPEA following incubation with 
phentolamine as an a-adrenergic antagonist: Graphical representation indicates no visual 
difference between mean artery tensions at different concentrations of BMPEA. One-way 
ANOVA confirms that artery tensions are not statistically different (p=0.6319, α=0.05). 
Phenylephrine following incubation with phentolamine as an a-adrenergic antagonist: Graphical 
representation indicates no visual difference between mean artery tensions at different 
concentrations of phenylephrine. One-way ANOVA confirms that artery tensions are not 
statistically different (p=0.7509, α=0.05). 
 
 
As graphical and statistical analysis did not indicate that BMPEA acts as a 
vasoconstrictor, it was tested as a potential vasodilator following pre-constriction with KCl. 
Average tensions at different BMPEA concentrations are shown in Table 4a. These do not 
indicate a change in tension with the administration of BMPEA. Isoproterenol was used as an 
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established positive control for β-adrenergic receptor-mediated vasodilation. However, artery 
tensions with increasing concentrations of isoproterenol do not indicate a decrease in tension. 
The average isoproterenol arterial tensions are presented in Table 4b. 
Table 4a. The Response of Mesenteric Arteries to Increasing Concentrations of BMPEA as a 
Potential Vasodilator 
n Concentration (M) Average tension (g) Standard Error 
10 1x10-7 19.85 1.99 
10 1x10-6 20.02 2.01 
10 1x10-5 20.08 2.01 
10 1x10-4 20.43 2.03 
10 1x10-3 21.24 2.08 
 
Table 4b. The Response of Mesenteric Arteries to Increasing Concentrations of Isoproterenol as 
Vasodilation Positive Control 
n Concentration (M) Average tension (g) Standard Error 
10 1x10-7 33.63 2.49 
10 1x10-6 33.34 2.49 
10 1x10-5 33.01 2.57 
10 1x10-4 33.21 2.67 
 
Graphical representation of BMPEA concentration-dependent mean arterial tensions 
following pre-constriction supports the observation that there was no decrease in tension as 
shown in figure 8a. This is confirmed with a one-way ANOVA which indicated no significant 
difference between the mean tensions with an F Ratio of 0.0750 and a Prob>F of 0.9894. 
Likewise, graphical representation of isoproterenol tensions is represented in Figure 8b, and 
indicates no visibly noticeable decrease in tension with administration of isoproterenol. This is 
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again confirmed with a one-way ANOVA which indicated no change in mean tensions with an F 
ratio of 0.0104 and a Prob>F of 0.9985.  
 
 
Figure 8a. Average Mesenteric Arterial Tension with Administration of BMPEA as a 
Potential Vasodilator after Pre-constriction with KCl. Graphical representation indicates no 
visual difference between mean artery tensions at different concentrations of BMPEA. This was 
confirmed with a one-way ANOVA with a p-value of 0.9894 α=0.05. 
 
 
Figure 8b. Average Mesenteric Arterial Tension with Administration of Isoproterenol as a 
Potential Vasodilator after Pre-constriction with KCl. Graphical representation indicates no 
visual difference between mean artery tensions at different concentrations of isoproterenol. This 
was confirmed with a one-way ANOVA with a p-value of 0.9985, α = 0.05. 
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 To confirm the response of α-adrenergic receptors in the mesenteric porcine vasculature 
studied, BMPEA and phenylephrine were administered in increasing concentrations following 
incubation with α-adrenergic antagonist phentolamine. Concentration dependent mean arterial 
tensions for BMPEA and phenylephrine following incubation with phentolamine are shown in 
Table 5a and 5b respectively. Graphical representation indicates no change in mean arterial 
tension with administration of increasing concentrations of BMPEA and phenylephrine with 
phentolamine blockade as indicated in Figure 7. The lack in tension change is confirmed with a 
one-way ANOVA which showed no significant difference between artery tensions for increasing 
concentrations of BMPEA (p=0.6319, α=0.05) or for increasing concentrations of phenylephrine 
(p=0.7509, α=0.05). 
Table 5a. The Response of Mesenteric Arteries to Increasing Concentrations of BMPEA Following 
Incubation with Phentolamine 
n Concentration (M) Average tension (g) Standard Error 
8 1x10-7 6.94 0.08 
8 1x10-6 6.77 0.09 
8 1x10-5 6.91 0.34 
8 1x10-4 6.53 0.17 
8 1x10-3 6.69 0.23 
 
Table 5b. The Response of Mesenteric Arteries to Increasing Concentrations of Isoproterenol 
Following Incubation with Phentolamine 
n Concentration (M) Average tension (g) Standard Error 
8 1x10-7 7.29 0.11 
8 1x10-6 7.14 0.14 
8 1x10-5 7.06 0.15 
8 1x10-4 7.26 0.25 
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BMPEA and isoproterenol were also tested in the presence of β-adrenergic antagonist 
propranolol following pre-constriction with KCl. The average arterial tensions for these are 
shown in Tables 6a and 6b respectively. These findings indicate no change in tension with the 
administration of BMPEA or isoproterenol following incubation with propranolol. This is not 
surprising as neither BMPEA nor isoproterenol precipitated a change in arterial tension, and 
there was no action to block with propranolol.  
 
Table 6a. The Response of Mesenteric Arteries to Increasing Concentrations of BMPEA Following 
incubation with Propranolol 
n Concentration (M) Average tension (g) Standard Error 
6 1x10-7 16.4 1.55 
6 1x10-6 16.51 1.57 
6 1x10-5 16.61 1.55 
6 1x10-4 16.68 1.39 
6 1x10-3 16.63 1.19 
 
Table 6b. The Response of Mesenteric Arteries to Increasing Concentrations of Isoproterenol 
Following Incubation with Propranolol 
n Concentration (M) Average tension (g) Standard Error 
6 1x10-7 14.26 2.97 
6 1x10-6 14.69 2.24 
6 1x10-5 16.42 1.61 
6 1x10-4 17.07 1.73 
 
Graphical analysis indicates no visibly noticeable change in average tensions for 
increasing concentrations of BMPEA or isoproterenol following propranolol incubation. These 
results are shown in Figures 9a and 9b respectively. The lack of change in arterial tension is 
confirmed with one-way ANOVA with an F ratio of 0.2597, Prob>F of 0.9009, and an F ratio of 
0.3396, Prob>F of 0.8486 for BMPEA and isoproterenol respectively. 
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Figure 9a. Average Mesenteric Arterial Tension with Administration of BMPEA Following 
Incubation with Propranolol as a β-adrenergic Antagonist. Graphical representation indicates 
no visual difference among mean artery tensions at different concentrations of phenylephrine. 
One-way ANOVA confirms that artery tensions are not statistically different (F ratio of 0.2597, 
Prob>F of 0.9009α=0.05). 
 
 
 
Figure 9b. Average Mesenteric Arterial Tension with Administration of Isoproterenol 
Following Incubation with Propranolol as a β-adrenergic Antagonist. Graphical 
representation indicates no visual difference between mean artery tensions at different 
concentrations of phenylephrine. One-way ANOVA confirms that artery tensions are not 
statistically different (F ratio of 0.3396, Prob>F of 0.8486, α=0.05). 
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Discussion 
 
 As a structurally similar, potential amphetamine replacement, BMPEA was expected to 
work on adrenergic receptors in the peripheral vasculature to elicit vasoactive responses. In 
particular, amphetamines have been shown to act on α-adrenergic receptors to elicit 
vasoconstrictive responses and BMPEA was expected have a similar response. This hypothesis 
was supported by animal studies that indicated BMPEA may play a role in increasing blood 
pressure and heart rate through vasoconstriction (Graham et al., 1944; Tainter et al., 1943; 
Warren et al., 1943).  
 Surprisingly, BMPEA did not elicit a statistically significant change in arterial tension 
when administered to viable arteries in concentrations between 1x10-7 M and 1x10-3 M (Prob>F 
of 0.1057). This was compared to the known α-adrenergic constrictor, phenylephrine, which 
showed a statistically significant increase in arterial tension that was dose-dependent (Prob>F  
less than 0.0001). While phenylephrine did not show a significant change in tension at the lowest 
concentrations (1x10-7M and 1x10-6M, p= 0.4829) there was significant change between      
1x10-7M and 1x10-5M with an average increase in tension of 11.67g (p<0.0001). Graphical 
analysis demonstrates the dose-dependent increase in arterial tension with a peak at 1x10-5M, 
which then dropped slightly at 1x10-4M.  However, this decrease in tension was not statistically 
significant.  
 Lack of constriction with BMPEA may indicate that it does not act on α-adrenergic 
receptors to elicit a sympathetic response. However, some drugs are known to differ in their 
effects, depending on the area of the body and the associated affinity or number of receptors in 
that organ. Thus the lack of BMPEA-mediated constriction may have been due to a decreased 
number of α-adrenergic receptors in porcine mesenteric vasculature, and constriction by 
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phenylephrine could be mediated through a different pathway.  This did not turn out to be the 
case however, as the presence of α-adrenergic receptors in the tested vasculature, as well as their 
role in phenylephrine constriction was confirmed using the α-adrenergic antagonist 
phentolamine. Incubation with phentolamine effectively blocked the action of phenylephrine, 
resulting in no statistical increase in artery tension with administration of phenylephrine. 
 Therefore, the lack of BMPEA-mediated vessel constriction would not seem to be 
indicative of a lack of α-adrenergic receptors in porcine mesenteric vasculature. It would instead 
indicate that BMPEA does not act on α-adrenergic receptors. While amphetamines act on α-
adrenergic receptors to achieve vasoconstriction in sympathetic pathways, they are also known to 
bind β-adrenergic receptors to induce vasodilation. BMPEA may also act on β-adrenergic 
receptors in select organ systems to cause vasodilation rather than vasoconstriction as 
hypothesized. However, administration of increasing concentrations of BMPEA to constricted 
vasculature did not yield a significant change in tension (F Ratio of 0.0750 and a Prob>F of 
0.9894), and no decrease in tension was noted upon graphical analysis. Likewise, there was no 
significant change in tension with administration of isoproterenol (F ratio of 0.0104 and a 
Prob>F of 0.9985).  
Lack of response to isoproterenol warrants investigation as this is a commonly used, well 
established β-adrenergic vasodilator. Upon examination after completion of experimentation, it 
was determined that the drug used was 8 years old. Further investigation is needed to determine 
whether the lack of response was due to the age of the drug. Lack of dilation may also be due to 
a lower affinity of β-adrenergic receptors in porcine mesenteric vasculature relative to other sites, 
or to a lower number of receptors. Another explanation may lie in the procedural plan, which 
utilizes pre-constriction with KCl. Our procedure did not allow for the buffer baths to be washed 
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following pre-constriction as this would result in a return to resting tension. Thus there may have 
been confounding effects resulting from KCl being present in the buffer bath, and it may have 
had a stronger constrictive effect than the dilation effect produced by isoproterenol. However, 
KCl works on ion-gated channels to change membrane potential, which thus opens calcium 
channels resulting in smooth muscle contraction, while isoproterenol works on ligand-gated 
channels. Thus, KCl should not act as a competitive inhibitor.  Additionally, nitroprusside was 
able to dilate arteries in the presence of KCl during viability testing. Nitroprusside mediates 
vasodilation by converting to NO and activating guanylate cyclase to increase intracellular 
production of cGMP, which in turn results in a decrease of calcium in the smooth muscle. This 
results in muscle relaxation. Further study is needed to determine which, if any, of these theories 
explains why isoproterenol addition did not result in vasodilation. 
 Despite the lack of dilation in response to isoproterenol and BMPEA, these substances 
were still tested in the presence of the β-adrenergic antagonist propranolol.  Confounding effects 
are not uncommon, and it was possible that BMPEA acts on both α and β receptors. If this were 
the case, the constrictive and dilative responses would cancel each other for a net result of zero 
change in tension. However, administration of BMPEA and isoproterenol after pre-incubation 
with propranolol and KCl yielded no statistically significant change in artery tension. Since 
isoproterenol did not produce a decrease in tension when treated without propranolol, and since 
no confounding effects were noted with the addition of propranolol incubation, further study is 
needed to confirm the presence of β- adrenergic receptors in the tested vasculature. This could be 
done by finding a different β agonist and establishing a vasodilation response with subsequent 
blocking with propranolol. Or, a western blot could be done to definitively establish the presence 
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of the β- adrenergic receptor. Further study is also needed to determine the affinity of those 
receptors for β-agonists such as isoproterenol, if the receptors are shown to be present.  
 Despite the lack of isoproterenol response, it can at least be said that BMPEA does not 
elicit a statistically significant response when administered as a potential dilator. Nor did it elicit 
a change in tension as a potential constrictor, indicating that BMPEA has no vascular effects in 
porcine mesenteric vasculature in the concentrations tested. It should be noted that BMPEA was 
administered in higher concentrations than would normally be present under normal physiologic 
conditions, and thus if any effects were present with normal, oral administration of this 
supplement, they would also be noted in our experimentation. Consequently, it can be stated with 
confidence that the aforementioned conclusion is correct, and that BMPEA does not have any 
vascular effects in swine mesenteric arteries. Unfortunately, there are no previous isolated 
vascular ring studies of BMPEA with which to compare these results, or indeed any vascular 
studies at all.  Before it can be said that BMPEA elicits no vascular effects at all, further study is 
needed in other organ systems because BMPEA could still elicit a vascular response in other 
areas of the body. As a possible sympathetic agent, BMPEA should also be tested for effects on  
gut motility, bronchial constriction and dilation, and cardiac action to determine whether it has 
any adverse effects.  
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Appendix 1: Excel Output Data
Vessel		tension	in	g
3-Oct-16 6-Oct-16 10-Oct-16 17-Oct-16
Drug	(dose) Column	1 Column	2 Column	3 Column	4 Column	1 Column	2 Column	3 Column	4 Column	1 Column	2 Column	3 Column	4 Column	1 Column	2 Column	3 Column	4
KCL KCl KCL KCL KCL
15mM 7.53 7.54 6.12 6.79 4.32 6.47 5.12 6.78 7.73 11.36 6.48 5.75 7.09
30mM 20.97 29.35 12.63 11.42 9.89 6.85 10.07 7.31 24.52 21.26 20.34 7.54 7.44
45mM 28.2 34.93 18.75 27.8 27.16 10.57 24.95 9.07 31.54 23.52 26.34 13.53 9.03
60mM 31.75 37.94 21.4 32.06 32.058 12.16 28.05 10.13 32.52 23.81 27.98 15.69 10.04
SNP SNP SNP SNP SNP
1x10-7	M 31.9 37.8 21.6 28.86 15.7 10.63 16.23 10.44 31.19 23.02 27.56 15.4 9.97
1x10-6M 31 36.8 21.64 28.71 15.23 10.53 15.44 10.19 30.37 21.41 26.99 15.24 9.98
1x10-5M 29.6 33.39 21.52 27.42 14.12 10.03 15.01 9.28 28.15 18.1 25.97 14.79 9.94
1x10-4M 26.01 25.46 20.89 24.95 10.21 8.91 12.42 7.5 19.85 13.01 21.54 12.42 9.7
Phenylephrine Phenylephrine Phenylephrine Phenylephrine
1x10-7	M 7.34 6.37 5.66 7.503 6.78 7.12 6.77 6.55 6.24 5.9
1x10-6M 19.4 9.5 12.9 13.765 6.87 8.45 6.67 6.7 8.5 6.6
1x10-5M 20.1 24.32 23.03 24.28 13.99 19.19 9.38 12.79 26.14 9.68
1x10-4M 12.34 13.42 20.93 31.7 15.98 14.2 10.15 15.17 21.83 7.98
BMPEA	constriction BMPEA	constriction BMPEA	constriction BMPEA	constriction
1x10-7	M 6.98 7.21 6.65 6.62 5.93 6.52 6.33 6.31 5.84 7.69
1x10-6M 6.9 7.1 5.73 6.33 5.49 6.16 5.94 5.96 5.38 7.13
1x10-5M 6.86 7 5.08 6.18 5.32 5.91 5.73 5.81 5.17 6.88
1x10-4M 6.74 6.97 4.83 6.08 5.23 5.83 5.56 5.6 5.05 6.67
1x10-3M 6.75 7.06 4.79 5.99 5.18 5.81 5.45 5.68 5.05 6.87
Isoproterenol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	dilation BMPEA	dilation
1x10-7	M 21.16 14.26 7.74
1x10-6M 21.25 14.27 7.87
1x10-5M 21.31 14.28 7.86
1x10-4M 21.48 14.36 7.88
1x10-3M 22.37 14.7 7.93
Phenelephrine	with	Phentolamine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	with	Phentolamine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
BMPEA	with	propranolol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Isoproterenol	with	propranolol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
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Vessel		tension	in	g
Drug	(dose)
KCL
15mM
30mM
45mM
60mM
SNP
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
Phenylephrine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	constriction
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Isoproterenol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	dilation
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Phenelephrine	with	Phentolamine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	with	Phentolamine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
BMPEA	with	propranolol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Isoproterenol	with	propranolol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
20-Oct-16 27-Oct-16 3-Nov-16 7-Nov-16
Column	1 Column	2 Column	3 Column	4 Column	1 Column	2 Column	3 Column	4 Column	1 Column	2 Column	3 Column	4 Column	1 Column	2 Column	3 Column	4
KCL KCL KCL KCL
7 7.9 7.08 7.56 6.68 6.45 12.7 6.67 8.04 8.54 6.48 5.65 7.02
6.91 21.13 19.97 28.58 5.8 23.55 25.89 15.19 36.76 35.96 13.24 26.96 27.75
11.79 25.46 24.47 34.68 8.927 24.48 27.14 34.09 43.73 42.78 15.07 43.86 31.5
16.9 26.67 25.26 35.58 13.9 25.78 26.95 35.18 42.58 43.81 15.46 44.49 31.56
SNP SNP SNP SNP
17.28 25.62 23.82 34.64 14.31 25.35 26.77 34.38 41.77 43.68 15.49 42.7 30.97
16.95 24.79 23.23 33.81 14.41 24.3 25.68 33.7 40.67 43.6 15.29 39.37 29.98
15.86 22.42 21.25 30.64 14.37 22.19 22.94 32.4 38.58 42 14.7 35.82 27.86
13.53 15.86 13.94 22.99 12.64 18.09 19.42 29.17 21.82 37.58 13.4 29.52 23.44
Isoproterenol Isoproterenol
35.97 28.74 42.45 24.94 46.15 35.36
36.79 27.81 42.42 24.86 45.89 35.48
37.41 26.29 42.42 24.93 45.9 35.61
37.81 25.52 42.56 25.45 46.6 37.31
BMPEA	dilation BMPEA	dilation
15.57 20.12 18.96 29.68 20.92 27.14 22.92
15.74 20.33 19.3 29.8 21.1 27.5 23.05
16.09 19.7 19.7 29.94 21.12 27.53 23.26
16.95 20.04 19.7 29.97 21.61 27.68 24.58
17.95 21.74 21.74 31.01 21.85 28.22 24.91
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Vessel		tension	in	g
Drug	(dose)
KCL
15mM
30mM
45mM
60mM
SNP
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
Phenylephrine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	constriction
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Isoproterenol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	dilation
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Phenelephrine	with	Phentolamine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	with	Phentolamine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
BMPEA	with	propranolol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Isoproterenol	with	propranolol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
10-Nov-16 9-Feb-17 16-Feb-17 23-Feb-17
Column	1 Column	2 Column	3 Column	4 Column	1 Column	2 Column	3 Column	4 Column	1 Column	2 Column	3 Column	4 Column	1 Column	2 Column	3 Column	4
KCL KCL KCL KCL
8.23 5.59 10.21 10.31 6.314 6.945 7.318 7.009 6.007 4.022 6.57 6.79 7.03 6.76 11.34 6.58
8.7 6.44 47.52 37.94 11.01 20.871 40.157 18.05 5.61 10.83 35.05 19.01 7.69 8.19 21.82 9.14
9.94 12.32 48.47 39.59 35.106 25.039 44.379 24.179 5.83 26.53 38.64 16.37 8.87 15.12 24.33 10.86
35.53 25.41 42.06 9.16 28.106 38.706 16.86 10.33 17.09 24.82 11.71
SNP SNP SNP SNP
12.16 15.937 46.83 39.45 33.65 24.9 40.74 24.76 9.578 27.53 38.37 16.73 10.34 17.11 24.81 11.73
12.816 16.08 45.51 39.15 32.38 24.37 39 24.19 9.851 26.49 37.97 16.59 10.33 17.12 24.81 11.64
12.57 15.49 43.84 37.52 29.01 21.9 31.47 22.55 8.94 23.72 37.31 16.03 8.9 16.04 21.83 10.34
10.7 10.49 30.5 28.78 18.94 18.94 23.2 20.64 7.307 19.63 35.71 14.812 7.42 15.23 19.23 8.01
Phenelephrine	with	Phentolamine Phenelephrine	with	Phentolamine Phenelephrine	with	Phentolamine
7.53 6.8 7.75 6.99 7.2 7.26
7.54 6.61 7.74 6.8 6.9 6.95
7.36 6.69 7.75 6.76 6.66 6.71
7.26 7.76 8.34 6.74 6.45 6.77
BMPEA	with	Phentolamine BMPEA	with	Phentolamine BMPEA	with	Phentolamine
6.88 7.15 6.98 7.06 7.105 6.48
6.72 7 6.88 6.93 6.78 6.26
6.53 6.92 6.76 8.86 6.57 6.09
6.45 6.9 7.03 6.75 6.42 5.62
6.42 7.46 6.94 6.73 7.18 5.63
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Vessel		tension	in	g
Drug	(dose)
KCL
15mM
30mM
45mM
60mM
SNP
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
Phenylephrine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	constriction
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Isoproterenol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	dilation
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Phenelephrine	with	Phentolamine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	with	Phentolamine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
BMPEA	with	propranolol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Isoproterenol	with	propranolol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
2-Mar-17 22-Mar-17 22-Mar-17 2-Mar-17
Column	1 Column	2 Column	3 Column	4 Column	1 Column	2 Column	3 Column	4 Column	1 Column	2 Column	3 Column	4 23-Mar Column	2 Column	3 Column	4
KCL
7.68 7.28 8.5 7.25
16.6 7.27 19.52 10.12
20.77 7.25 22.57 11.64
22.94 7.22 23.07 11.89
SNP
22.6 7.22 22.36 11.88
21.56 7.23 20.25 11.84
20.4 7.21 16.8 11.75
14.715 7.18 11.59 10.37
Phenelephrine	with	Phentolamine
7.24 7.53
7.08 7.47
7.01 7.57
7.04 7.74
BMPEA	with	Phentolamine
6.93
6.79
6.64
6.57
6.5
BMPEA	with	propranolol BMPEA	with	propranolol BMPEA	with	propranolol
16.78 22.86 14.26 18.08 12.11 14.31
16.76 22.98 14.65 18.44 12.13 14.12
16.58 22.87 15.03 18.83 12.21 14.14
16.56 21.57 15.78 19.53 12.29 14.33
16.55 21.56 16.52 18.73 12.09 14.32
Isoproterenol	with	propranolol Isoproterenol	with	propranolol Isoproterenol	with	propranolol
20.3 10.29 17.58 16.49 19.59 1.32
20.21 10.29 17.57 6.72 19.92 13.43
20.18 10.26 17.8 16.55 20.27 13.44
21.55 10.58 18.27 16.88 21.16 14
43	
	
 
 
Vessel		tension	in	g
Drug	(dose)
KCL
15mM
30mM
45mM
60mM
SNP
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
Phenylephrine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	constriction
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Isoproterenol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	dilation
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Phenelephrine	with	Phentolamine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
BMPEA	with	Phentolamine
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
BMPEA	with	propranolol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
1x10-3M
Isoproterenol	with	propranolol
1x10-7	M
1x10-6M
1x10-5M
1x10-4M
Avg	tension: Standar	error	of	the	mean
7.273586957 0.248085585
18.23517391 1.590412379
23.93847826 1.719099621
27.67958621 1.883469698
Avg	tension: Standar	error	of	the	mean
25.9925 1.75387608
25.36071053 1.686700129
23.65 1.569095063
19.0505 1.257054202
Avg	tension: Standar	error	of	the	mean
6.6233 0.189967252
9.9355 1.329753204
18.29 2.007423445
16.37 2.175466744
Avg	tension: Standar	error	of	the	mean
6.608 0.17940519
6.212 0.202883656
5.994 0.227567817
5.856 0.235306892
5.863 0.252441632
Avg	tension: Standar	error	of	the	mean
35.60166667 2.526320183
35.54166667 2.568416957
35.42666667 2.669169659
35.875 2.761973751
Avg	tension: Standar	error	of	the	mean
19.847 1.997616385
20.021 2.008528732
20.079 2.01275458
20.425 2.028776451
21.242 2.083114549
Avg	tension: Standar	error	of	the	mean
7.2875 0.109246608
7.13625 0.141584623
7.06375 0.154572423
7.2625 0.226059016
Avg	tension: Standar	error	of	the	mean
6.940714286 0.084883874
6.765714286 0.091751661
6.91 0.339130541
6.534285714 0.174804069
6.694285714 0.225175668
Avg	tension: Standar	error	of	the	mean
16.4 1.54973331
16.51333333 1.570608516
16.61 1.549991398
16.67666667 1.386284402
16.62833333 1.350075101
Avg	tension: Standar	error	of	the	mean
14.26166667 2.966986593
14.69 2.240432994
16.41666667 1.609423637
17.07333333 1.730313395
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Appendix 2: Statistical Outputs 
KCl one-way ANOVA and Tukey post hoc testing: 
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SNP one-way ANOVA and Tukey post hoc testing:
 
 
46	
	
Phenylephrine one-way ANOVA and Tukey post hoc testing:
 
 
47	
	
BMPEA constrictor one-way ANOVA and Tukey post hoc testing:
 
 
48	
	
Isoproterenol one-way ANOVA and Tukey post hoc testing: 
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BMPEA dilator one-way ANOVA and Tukey post hoc testing: 
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BMPEA with phentolamine one way ANOVA:
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Phenylephrine with phentolamine one way ANOVA: 
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BMPEA with propranolol one-way ANOVA: 
 
53	
	
Isoproterenol with propranolol one way ANOVA: 
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